3-溴-5-硝基吡啶 | 15862-30-3

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 3-溴-5-硝基吡啶
• 中文别名: 3-溴-5-硝基嘧啶；2-溴-5-硝基吡啶
• 英文名称: 3-bromo-5-nitropyridine
• CAS: 15862-30-3
• 化学式: C₅H₃BrN₂O₂
• mdl: MFCD04114216
• 分子量: 202.995
• InChiKey: WHYJVHQKKJHXTB-UHFFFAOYSA-N

物化性质

• 熔点：
  111-115℃
• 沸点：
  251.6±20.0 °C(Predicted)
• 密度：
  1.833±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38,R25,R41
• WGK Germany：
  3
• 海关编码：
  2933399090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P280,P301+P310+P330,P305+P351+P338+P310
• 危险品运输编号：
  2811
• 危险性描述：
  H301,H318
• 储存条件：
  室温。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Bromo-5-nitropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H318: Causes serious eye damage
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-5-nitropyridine
CAS number: 15862-30-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H3BrN2O2
Molecular weight: 203.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (3-Bromo-5-nitropyridine)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴-5-硝基吡啶 在 四羟基二硼 、 palladium on activated charcoal 、 水 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以96%的产率得到5-溴-3-氨基吡啶
  参考文献：
  名称：

  一种芳硝基还原为芳胺的方法

  摘要：

  本发明涉及了一种芳硝基还原为芳胺的方法：（1）该方法以芳硝基化合物为原料，以水为氢源，以廉价易得的钯化合物作为催化剂，四羟基二硼为添加剂，还原硝基得到产物；（2）该方法以芳硝基化合物为原料，以廉价易得的铜盐为催化剂，四羟基二硼为添加剂，还原硝基得到产物；（3）该方法以芳硝基化合物为原料，以水为氢源，四羟基二硼为添加剂，不需要金属催化剂，就可以还原硝基得到产物。本发明所提供芳胺的制备方法，反应条件温和，成本低、环境友好、产率高，适合工业化生产。

  公开号：

  CN106800493B
• 作为产物：
  描述：

  5-溴吡啶-3-硼酸频哪醇酯 在 copper diacetate 、 三乙胺 、 sodium nitrite 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以0.103 g的产率得到3-溴-5-硝基吡啶
  参考文献：
  名称：

  带有芳基化的芳烃的邻位/对位导向基团的亚硝化

  摘要：

  在本文中，我们报道了荟萃芳烃的-nitration轴承邻/对位用铱催化的C-H硼化反应之后是新开发的铜（II）粗频哪醇的芳基硼酸酯入的催化的变换引导组（多个）以一锅的方式对应的硝基芳烃。该协议允许的合成元-nitrated芳烃是乏味来制备或使用现有的方法需要多步合成。该反应可耐受多种邻位/对位导向基团，例如-F，-Cl，-Br，-CH 3，-Et，-i Pr -OCH 3和-OCF 3。它还提供对π电子缺陷杂环的硝基衍生物（例如吡啶和喹啉衍生物）的区域选择性访问。该方法的应用在复杂分子的后期修饰中以及在以克级制备到FDA批准的药物Nilotinib途中的中间体中得到了证明。最后，我们证明了通过该策略获得的硝基产物也可以通过Baran的胺化方案直接转化为苯胺或受阻胺。

  DOI：

  10.1002/chem.201901633

文献信息

• Selective Chemical Functionalization at N6-Methyladenosine Residues in DNA Enabled by Visible-Light-Mediated Photoredox Catalysis
  作者：Manuel Nappi、Alexandre Hofer、Shankar Balasubramanian、Matthew J. Gaunt

  DOI：10.1021/jacs.0c10616

  日期：2020.12.23

  Selective chemistry that modifies the structure of DNA and RNA is essential to understanding the role of epigenetic modifications. We report a visible-light-activated photocatalytic process that introduces a covalent modification at a C(sp3)-H bond in the methyl group of N6-methyl deoxyadenosine and N6-methyl adenosine, epigenetic modifications of emerging importance. A carefully orchestrated reaction

  修饰 DNA 和 RNA 结构的选择性化学对于理解表观遗传修饰的作用至关重要。我们报告了一种可见光激活的光催化过程，该过程在 N6-甲基脱氧腺苷和 N6-甲基腺苷的甲基 C(sp3)-H 键上引入共价修饰，这是新兴重要性的表观遗传修饰。精心策划的反应结合了硝基吡啶的还原反应，形成亚硝基吡啶自旋捕获剂，以及精确选择性的叔胺介导的 N6-甲基上的氢原子抽象，形成 α-氨基自由基。假定的 α-氨基自由基与亚硝基吡啶交叉偶联产生稳定的缀合物，在 N6-甲基-腺苷上安装标签。我们证明，可以从复杂的混合物中富集含 N6-甲基脱氧腺苷的寡核苷酸，这为识别基因组 DNA 和 RNA 中的这种修饰的应用铺平了道路。
• [EN] PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS<br/>[FR] INHIBITEURS DE PROTÉINE KINASE ET LEURS UTILISATIONS POUR LE TRAITEMENT DE MALADIES ET DE PROBLÈMES DE SANTÉ
  申请人：UNIV HOUSTON SYSTEM

  公开号：WO2020232190A1

  公开（公告）日：2020-11-19

  Identified compounds demonstrate protein kinase inhibitory activity. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2) and/or receptor interacting kinase 3 (RIPK3). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 or RIPK3 could provide therapeutic benefit. Compounds that function as RIPK3 inhibitors provide therapeutic benefit in the treatment of inflammatory and degenerative conditions.

  已识别的化合物具有蛋白激酶抑制活性。更具体地说，这些化合物被证实可以抑制受体相互作用激酶2（RIPK2）和/或激活素样激酶2（ALK2）和/或受体相互作用激酶3（RIPK3）。既能作为RIPK2/ALK2双重抑制剂，或优先抑制RIPK2或ALK2或RIPK3的化合物，可能提供治疗益处。作为RIPK3抑制剂的化合物在治疗炎症和退行性病症方面提供治疗益处。
• [EN] CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE CHROMÉNOPYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PHOSPHATIDYLINOSITOL PHOSPHATE KINASE
  申请人：PETRA PHARMA CORP

  公开号：WO2019126730A1

  公开（公告）日：2019-06-27

  The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are described herein.

  这项发明涉及PI5P4K抑制剂，用于治疗癌症、神经退行性疾病、炎症性疾病和代谢性疾病，具有以下式（I）；其中A1、A2、G、R1、R2、R3、R4和W如本文所述。
• PYRIDAZINONES AS PARP7 INHIBITORS
  申请人：Ribon Therapeutics Inc.

  公开号：US20190330194A1

  公开（公告）日：2019-10-31

  The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.

  本发明涉及吡啶并嗪酮和相关化合物，它们是PARP7的抑制剂，并且在癌症治疗中很有用。
• Reduction of aromatic and aliphatic nitro groups to anilines and amines with hypophosphites associated with Pd/C
  作者：Marc Baron、Estelle Métay、Marc Lemaire、Florence Popowycz

  DOI：10.1039/c3gc37024k

  日期：——

  The reduction of aromatic and aliphatic nitro groups to anilines and amines is performed with good yield and selectivity in short reaction times. A mixture of sodium hypophosphite and phosphinic acid is used in the presence of a heterogeneous catalyst 2.5 mol% of Pd/C (5%) in a biphasic water/2-MeTHF system.

  芳香和脂肪族硝基化合物在较短的反应时间内，以良好的收率和选择性还原为苯胺和胺。在多相催化剂2.5 mol%的Pd/C（5%）存在下，使用次磷酸钠和膦酸的混合物在两相水/2-甲基四氢呋喃体系中进行还原。